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observed in 6 and 8 measurements (total of 26.9%), respectively, but 
only 2 measurement were over 10%. Four of the six measurements on 
the anal verge showed difference of 5% or more between the 
calculated and estimated dose.  
Conclusions: With high dose gradients in VMAT treatments it is 
essential to know the correct position of TLDs in order to properly 
analyze the results of in-vivo dosimetry. This new procedure seems 
dealing with this issue, allowing validating and monitoring doses 
delivered to patients.  
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Purpose/Objective: The clinical importance of the discrepancies 
detected in pre-treatment IMRT QA is often difficult to interpret. This 
seems to be possible by using a recent commercial software, 3DVH 
(SunNuclear, USA), that relies on field QA data to reconstruct a 3D 
dose distribution in the patient. A study is planned in our Institute to 
compare IMRT calculated dose distributions to the delivered ones 
reconstructed from QA results. In this work, we present the feasibility 
study dealing with the validation of the used software and methods.  
Materials and Methods: The validation study introduced deliberate 
errors in a sample of clinical plans to simulate delivery/calculation 
errors (modified plan). Then the error-free beams were used to 
generate virtual planar QA measures and input to SNC Patient 
software, which generates a PDP (Planned Dose Perturbation) file 
containing information about QA and calculated doses. The DICOM RT 
files together with the PDP file were loaded into the 3DVH software to 
reconstruct the error-free 3D patient doses by perturbing the modified 
plan. MU delivery errors of ±4% were simulated in the TPS. MLC errors 
were simulated by opening and closing leaves of one MLC bank by 1 
mm or 2 mm. The comparison between the 3DVH reconstructed dose 
and the original unmodified plan is performed in terms of the main 
DVH parameters of PTVs and OARs. Finally, the 3DVH software was 
applied to a sample of 10 head-and-neck (H&N, highly modulated due 
to simultaneous delivery of different doses to 3 PTVs) clinical plans 
and relative pre-tx QA performed with a diode array (Mapcheck2, 
SunNuclear, USA). The 3D γ-matching rates of the reconstructed plans 
are compared with the γ-passing rate of per-beam planar measures to 
detect possible correlations. 
Results: Fig. 1 shows the impact on the main DVH parameters of the 
simulated errors, as given by the 3DVH software. As expected, dose 
(MU) errors have a larger impact on PTVs than changes in MLC 
positions. In particular, a ± 4% change in MU is associated to a change 
in the PTVs mean dose of + 4.16 ± 0.01% and -3.84 ± 0.01%, 
respectively, suggesting a slight bias of 0.2%. Similar results have been 
obtained for OARs’ mean dose, while the impact of MLC error results 
more important than MU change. As for the capability of the 3DVH 
software to accurately reconstruct the original plan from the modified 
plan by using the virtual planar measures, all results give an almost 
perfect match of the 2 plans. Small differences are found only for 
very small volumes such as parotids. Finally, the application of 3DVH 
to our 10 H&N clinical sample has shown no significant correlation 
between the γ passing rates of single beam QA and the 3D matching 
rate of the reconstructed plan; better correlation is found with the 
minimum value of γ passing rates obtained in QA per-beam measures. 
 
  
Conclusions: Validation of 3DVH software against TPS has shown good 
results. Application to clinical plans using real QA data shows that the 
dosimetric discrepancies detected in individual field QA are not 
correlated to the γ of the reconstructed plan.  
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Purpose/Objective: The purpose of the study is to clinically validate 
the Gated dose delivery for mobile targets with VMAT using Electronic 
Portal Imaging Device (EPID). 
Materials and Methods: The advantage of Gated RapidArc (G-RA) 
technology is that it reduce the margin of Internal Target volume (ITV) 
which reduces the dose to OAR's adjacent to the mobile tumours. G-
RA was delivered using the Varian Real-Time Position Management 
(RPM) system which uses external retro reflective infrared markers to 
generate gate-open signals of different durations. To assure the 
proper dynamic dose delivery and MLC position of G-RA treatments, 
we selected five lung cases and RA plans were created in Varian 
Eclipse(v10) Treatment Planning System (TPS). Verification plans were 
generated using portal dosimetry and Portal Dose Prediction Algorithm 
(PDIP v10) is used to predict the portal dose at the isocenter. All plans 
were executed in Clinac-iX treatment machine and portal dose images 
were acquired using EPID, while Infrared reflecting box is periodically 
moved to provide gating signal for RPM system.To evaluate the 
accuracy of dose delivery, measurements were performed for 
different duty cycles (80%, 50% & 20%) and were compared with the 
portal doses of non-gated RA of the same plan. Earlier the non-Gated 
RA plans were compared with the TPS predicted portal dose. Area 
gamma and dose difference was analyzed in portal dosimetry 
workspace in Eclipse for the criteria 2mm Distance to Agreement 
(DTA) & 2% Dose Difference (DD) and 3mm & 3%.MLC Dynalog files 
were analyzed and expressed as root mean square (RMS) of the 
deviations of individual leaves during treatment delivery. 
Results: The accuracy of gated RapidArc dose delivery is compared 
against the non gated RapidArc delivery using electronic portal 
imaging device. The average area gamma less than 1 for duty cycles 
80%, 50%,& 20% were 99.84(±0.19), 99.5(±0.29), 87.52(±1.57) for 2mm 
DTA & 2% DD and 100.0(±0.0), 99.98(±0.05), 98.96(±0.87) for 3mm 
DTA & 3% DD respectively. Average of maximum error root mean 
square for all MLC positions were 0.074mm (±0.0059), 




Conclusions: Gated RapidArc delivery validated using EPID and results 
exhibits that there is good agreement between delivery of G-RA and 
non gated RapidArc. For fast, accurate and its highspatial resolution, 
EPID can be used as a verification tool for gated RA delivery. 
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Purpose/Objective: Radiochromic films are recognized to be suitable 
for patient specific QA in IMRT treatments verification because of high 
spatial resolution, near-tissue equivalence and weak energy 
dependence. Challenges in radiochromic films dosimetry using a 
multichannel flatbed scanner, are related to uncertainties due mainly 
to scanner non-uniformity and film thickness difference within films 
